Abstract
Patients who have sustained a traumatic brain injury (TBI) exhibit clinical symptoms of widely varying types and severities. In contrast, because of cost, experimental flexibility, and animal welfare, preclinical rodent models of TBI are designed to exhibit relatively homogeneous symptoms. This disconnect may explain why drugs developed using rodent models have universally failed in clinical studies. We suggest that drug development for TBI could benefit from preclinical studies using non-mammalian animals, where cost, experimental flexibility, and animal welfare are less of an issue and variables that affect clinical symptoms, including genotype, age, and environmental factors, can be more extensively investigated.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics. 2010;7:115–26.
Shouten JW. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature. Curr Opin Crit Care. 2007;13:134–42.
Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma. 2002;19:503–57.
Marklund N, Bakshi A, Castelbuono DJ, et al. Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr Pharm Des. 2006;12:1645–80.
• Kabadi SV, Faden AI. Neuroprotective strategies for traumatic brain injury: Improving clinical translation. Int J Mol Sci. 2014;15:1216–36. This paper reviews strategies for improving clinical studies of candidate TBI treatments.
Deutsch ER, Espinoza TR, Fahim A. Progesterone’s role in neuroprotection, a review of the evidence. Brain Res. 2013;1530:82–105.
Wright DW, Kellerman AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49:391–402.
Xiao G, Wei J, Yan W, et al. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care. 2008;12:R61.
Wright DW, Yeatts SD, Silbergleit R, et al. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014;371:2457–66.
Skolnick BE, Maas AI, Narayan RK, et al. A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med. 2014;371:2467–76.
•• Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. Nat Rev Neurosci. 2013;14:128–42. This review provides a comprehensive description of mammalian models of TBI and rationales for using larger animals to study clinically relevant pathologies.
O’Connor WT, Smyth A, Gilchrist MD. Animal models of traumatic brain injury: a critical evaluation. Pharmacol Ther. 2011;130:106–13.
Petraglia AL, Dashnaw ML, Turner RC, et al. Models of mild traumatic brain injury: translation of physiological and anatomic injury. Neurosurgery. 2014;75:S34–49.
Morganti-Kossmann MC, Yan E, Bye N. Animal models of traumatic brain injury: is there an optimal model to reproduce human brain injury in the laboratory? Injury. 2010;41:S10–3.
Swindle MM, Makin A, Herron AJ, et al. Swine as models in biomedical research and toxicology testing. Vet Pathol. 2012;49:344–55.
Capitanio JP, Emborg ME. Contributions of non-human primates to neuroscience research. Lancet. 2008;371:1126–35.
Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. Exp Neurol. 2013;246:35–43.
Pilitsis JG, Rengachary SS. Complications of head injury. Neurol Res. 2001;23:227–36.
Zygun DA, Kortbeek JB, Fick GH, et al. Non-neurologic organ dysfunction in severe traumatic brain injury. Crit Care Med. 2005;33:654–60.
Kemp CD, Johnson JC, Riordan WP, et al. How we die: the impact of nonneurologic organ dysfunction after severe traumatic brain injury. Am Surg. 2008;74:866–72.
Masel B, DeWitt DS. Traumatic brain injury: a disease process, not an event. J Neurotrauma. 2010;27:1529–40.
Wang HC, Sun CF, Chen H, et al. Where are we in the modeling of traumatic brain injury? Models complicated by secondary brain insults. Brain Inj. 2014;28:1491–503.
Kovacs SK, Leonessa F, Ling GS. Blast TBI models, neuropathology, and implications for seizure risk. Front Neurol. 2014;5:47.
Santoriello C, Zon L. Hooked! Modeling human disease in zebrafish. J Clin Invest. 2012;122:2337–43.
Pandey UB, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev. 2011;63:411–36.
Markaki M, Tavernarakis N. Modeling human diseases in Caenorhabditis elegans. Biotechnol J. 2010;5:1261–76.
Howe K, Clark MD, Torroja CF, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496:498–503.
Fortini ME, Skupski MP, Boguski MS, et al. A survey of human disease gene counterparts in the Drosophila genome. J Cell Biol. 2000;150:23–30.
Culetto E, Sattelle DB. A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum Mol Genet. 2000;9:869–77.
Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet. 2007;8:353–67.
Bellen HJ, Tong C, Tsuda H. 100 years of Drosophila research and its impact on vertebrate neuroscience: a history lesson for the future. Nat Rev Neurosci. 2010;11:514–22.
Silverman GA, Luke CJ, Bhatia SR, et al. Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans. Pediatr Res. 2009;65:10–8.
Giacomotto J, Ségalat L. High-throughput screening and small animal models, where are we? Br J Pharmacol. 2010;160:204–16.
Reichert H. Evolutionary conservation of mechanisms for neural regionalization, proliferation and interconnection in brain development. Biol Lett. 2009;5:112–6.
Leyssen M, Ayaz D, Hebert SS, et al. Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. EMBO J. 2005;24:2944–55.
Hockey KS, Hubbard WB, Sajja VS. A new model for mild blast injury utilizing Drosophila melanogaster—biomed 2013. Biomed Sci Instrum. 2013;49:134–40.
•• Katzenberger RJ, Loewen CA, Wassarman DR, et al. A Drosophila model of closed head traumatic brain injury. Proc Natl Acad Sci USA. 2013;110:E4152–9. This paper describes the development and characterization of a fly TBI model.
Katzenberger RJ, Loewen CA, Bockstruck RT, et al. A method to inflict closed head traumatic brain injury in Drosophila. J Vis Exp. 2015;30:e52905.
• Katzenberger RJ, Chtarbanova S, Rimkus SA, et al. Death following traumatic brain injury in Drosophila is associated with intestinal barrier dysfunction. Elife. 2015;5:4. This paper describes the application of GWAS analysis in the fly model to uncover genes potentially associated with TBI pathologies.
Günther M, Al Nimer F, Gahm C, et al. iNOS-mediated secondary inflammatory response differs between rat strains following experimental brain contusion. Acta Neurochir. 2012;154:689–97.
Al Nimer F, Lindblom R, Ström M, et al. Strain influences on inflammatory pathway activation, cell infiltration, and complement cascade after traumatic brain injury in the rat. Brain Behav Immun. 2013;27:109–22.
Reid WM, Rolfe A, Register D, et al. Strain-related differences after traumatic brain injury in rats. J Neurotrauma. 2010;27:1243–53.
Tan AA, Quigley A, Smith DC, et al. Strain differences in response to traumatic brain injury in Long-Evans compared to Sprague-Dawley rats. J Neurotrauma. 2009;26:539–48.
Fox GB, LeVasseur RA, Faden AI. Behavioral responses of C57BL/6, FVB/N, and 129/SvEMS mouse strains to traumatic brain injury: implications for gene targeting approaches to neurotrauma. J Neurotrauma. 1999;16:377–89.
Dardiotis E, Fountas KN, Dardioti M, et al. Genetic association studies in patients with traumatic brain injury. Neurosurg Focus. 2010;28:E9.
Failla MD, Kumar RG, Peitzman AB, et al. Variation in the BDNF gene interacts with age to predict mortality in a prospective, longitudinal cohort with severe TBI. Neurorehabil Neural Repair. 2015;29:234–46.
Dalla Libera AL, Regner A, de Paoli J, et al. IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury. Brain Inj. 2011;25:365–9.
Hoh NZ, Wagner AK, Alexander SA, et al. BCL2 genotypes: functional and neurobehavioral outcomes after severe traumatic brain injury. J Neurotrauma. 2010;27:1413–27.
Mackay TF, Richards S, Stone EA, et al. The Drosophila melanogaster genetic reference panel. Nature. 2012;482:173–8.
Katzenberger RJ, Ganetzky B, Wassarman DA. The gut reaction to traumatic brain injury. Fly. 2015;9:68–74.
Acknowledgments
We thank members of the Ganetzky and Wassarman labs for their contributions to studies of the fly TBI model.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Traumatic Brain Injury Rehabilitation.
Rights and permissions
About this article
Cite this article
Ganetzky, B., Wassarman, D.A. Non-mammalian Animal Models Offer New Perspectives on the Treatment of TBI. Curr Phys Med Rehabil Rep 4, 1–4 (2016). https://doi.org/10.1007/s40141-016-0107-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40141-016-0107-8